An observational study in AKI - Acute Kidney Injury, Cardiac Surgery and Fluid Therapy, sponsored by FIZE Medical ltd. Recruiting at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by FIZE Medical ltd · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Acute Kidney Injury with a site in Israel — 3 open to participants now, 4 under way, none of them phase 3. Acute Kidney Injury · Israel.
Among the 13 studies in Acute Kidney Injury with a site in Israel, this one is the only one that started in 2026, is one of 6 observational ones, and was the 13th registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →3 of the 13 studies in Acute Kidney Injury with a site in Israel are open now. Recruiting first, the newest first:
Indiana University · Sites in Israel, United States, Argentina and 30 more countries
Ages 0 min–2 wk
Meir Medical Center · Sites in Israel
Ages 18–100
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is below the median of 160 across 814 observational studies indexed under Acute Kidney Injury.
Median enrollment 30 across the 7 interventional studies, 250 across the 6 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 13 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with FIZE Medical ltd as lead sponsor.
FIZE Medical ltd has 1 study filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
2 of the studies in Acute Kidney Injury with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT07022314FIZE Medical ltdUrine Output Response to Fluid and Diuretic Therapy in Cardiac ICU Patients Monitored With FIZE kUO® | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Acute Kidney Injury with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational study evaluates the real-time urine output response to fluid therapy and diuretics in cardiothoracic intensive care unit (CTICU) patients monitored with the FIZE kUO® device. The study aims to assess how continuous urine output monitoring can inform fluid management and improve patient outcomes post-cardiac surgery.
The study involves adult patients undergoing coronary artery bypass graft (CABG) or valve replacement/repair surgeries. Utilizing the FIZE kUO® device, continuous urine output data will be collected to analyze responses to hemodynamic interventions, including fluid boluses and diuretics. Secondary objectives include assessing urine output differences in patients with and without postoperative acute kidney injury (AKI), responses to vasopressors, and capturing real-time urine output data from FIZE kUO® for observational analysis.
Adult cardiac surgery patients in the cardiothoracic ICU who require continuous urine output monitoring and are connected to the FIZE kUO® device as part of routine clinical care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients (≥18 years old) undergoing coronary artery bypass graft (CABG) and/or valve surgery, admitted postoperatively to the Cardiothoracic Intensive Care Unit (CTICU), and connected to the FIZE kUO® device for real-time urine output monitoring as part of standard care.
Device: FIZE kUO®
FIZE kUO® is a commercially available, non-invasive device used for continuous, minute-by-minute real-time urine output monitoring in patients with an indwelling Foley catheter. In this observational study, the device is used during and after cardiac surgery as part of routine clinical care. Urine output data, along with additional clinical parameters, are collected throughout the study for research analysis.
Urine output response to fluid boluses and diuretics
Change in urine output measured by FIZE kUO® during 2 hours before and after fluid or diuretic administration.
Time frame: 4 hours (2 hours before and 2 hours after intervention)
Difference in urine output during surgery between patients with and without AKI
Comparison of urine output measured by FIZE kUO® in patients who develop AKI vs. those who do not
Time frame: Perioperative/Periprocedural
Urine output response to vasopressors
Change in urine output measured by FIZE kUO® before and after vasopressor administration
Time frame: 4 hours (2 hours before and 2 hours after intervention)
Evaluation of FIZE kUO® Urine Output Monitoring Compared to Manual Measurement
Comparison of FIZE kUO® urine output with manual measurement of urine output
Time frame: Through ICU stay, up to 5 days
Started Jan 2026 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.
Of 365 observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 17 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.